NAFLD
| 3 min read
Scientists found that the Kisspeptin hormone activates enzymes that stop lipid formation in the mouse liver, suggesting that it has potential as a drug target for treating non-alcoholic fatty liver disease.
| 10+ min read
Through academic, industry, and governmental partnerships, scientists validate and develop non-invasive diagnostics for non-alcoholic fatty liver disease. These tests are set to replace the invasive and risky gold standard: liver biopsy.
| 3 min read
Median Technologies teams up with UC San Diego on diagnosing liver fibrosis severity in NASH patients
| 3 min read
iBiopsy study shows promise in diagnosing severity of disease in patients
| 2 min read
Transcriptome sequencing of patients with liver disease reveals gene expression changes that could help to track disease severity and progression
| 3 min read
Owlstone study pinpoints limonene for early diagnosis of NASH and NAFLD
Page 1 of 1 - 6 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Overcoming barriers in gene therapy
Advanced gene editing, delivery, and analytical tools are driving better gene therapies.
A multiomic approach to profiling brain tumors
Probing the molecular drivers of brain metastasis reveals novel therapeutic targets.
Enhancing immune cell profiling with digital technologies
Software innovations help researchers decode immune complexity in cancer.
